Back to results
US 2003/0166251 A1Published application
High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splicing acceptor
AssigneeViroMed Co., Ltd.
InventorsSun-Young Kim, Seung-Shin Yu, Jun-Tae Lee
Life of this patent
Estimating the term…
Abstract
The present invention provides a safe and highly efficient retroviral vector derived from the MLV (murine leukemia virus) for use in gene therapy, which lacks viral coding sequences but contains the genetically engineered EF Iα non-coding sequence harboring splicing acceptor.
Claims11
A retroviral vector derived from the murine leukemia virus (MLV) vector, comprising
- 1 ) a part of the non-coding sequence of the elongation factor EF1α as an heterologous gene-derived non-coding sequence inserted upstream from the multi-cloning site, and
- 2) a mutation introduced downstream from the splicing acceptor within the non-coding sequence of EF1α,
- said retroviral vector lacking viral-coding sequences.
Dependencies are inferred from the claim text.